Anakinra treatment in drug-resistant Behcet’s disease: a case series (Q58326155)

Francesco Caso

9

0 references

Gabriele Simonini

Gabriele Simonini

7

0 references

Luca Cantarini

Luca Cantarini

1

0 references

Leonardo Punzi

Leonardo Punzi

13

0 references

Mauro Galeazzi

14

Mauro Galeazzi

0 references

Charles A. Dinarello

4

Charles A. Dinarello

0 references

Rolando Cimaz

15

Rolando Cimaz

0 references

Bruno Frediani

11

Bruno Frediani

0 references

Donato Rigante

5

Donato Rigante

0 references

author name string

Antonio Vitale

2

0 references

Perla Scalini

3

0 references

Rossella Franceschini

6

0 references

Giulia Borsari

8

0 references

Ilaria Bertoldi

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

12

0 references

publication date

5 December 2013

0 references

published in

Clinical Rheumatology

0 references

volume

34

0 references

issue

7

0 references

page(s)

1293-1301

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Evaluation of current therapeutic strategies in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Resistant Behçet disease responsive to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

MEFV mutations in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

The fresco of autoinflammatory diseases from the pediatric perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Interferon therapy in rheumatic diseases: state-of-the-art 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Adalimumab: a new modality for Behçet's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

On-demand anakinra treatment is effective in mevalonate kinase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Cytokines and Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

CSF levels of cytokines in neuro-Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Infliximab for patients with neuro-Behcet's disease: case series and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2443-8

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis

1 reference

12 December 2020

Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity

1 reference

12 December 2020

Successful use of canakinumab in a patient with resistant Behçet's disease

1 reference

12 December 2020

Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab

1 reference

12 December 2020

CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells

1 reference

12 December 2020

Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity

1 reference

12 December 2020

Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab

1 reference

12 December 2020

Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

1 reference

12 December 2020

Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.

1 reference

12 December 2020

Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.

1 reference

12 December 2020

Association of the R92QTNFRSF1Amutation and extracranial deep vein thrombosis in patients with Behçet's disease

1 reference

12 December 2020

Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease

1 reference

12 December 2020

Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome

1 reference

12 December 2020

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease

1 reference

12 December 2020